Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients-A Single-Institution Retrospective Review
{{output}}
Blinatumomab, a CD19xCD3 bispecific T-cell engager, has become standard therapy for children with de novo B-cell acute lymphoblastic leukemia (B-ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients. At o... ...
